RSS   Newsletter   Contact   Advertise with us
Post Online Media
Post Online Media Magazine

Asceneuron appoints Peter Van Vlasselaer to chair the board

Share on Twitter Share on LinkedIn
Staff Writer | Lausanne, Switzerland |
Peter Van VlasselaerAsceneuron, a healthcare company, announced the appointment of Peter Van Vlasselaer as chair of the board of directors.
Dr. Van Vlasselaer has over 20 years executive and entrepreneurial experience in the biotech industry.

Dr. Van Vlasselaer was most recently the Founder, President and Chief Executive Officer of ARMO Biosciences, Inc. which shortly after its public offering was acquired by Eli Lilly.

Prior to this, he was President and Chief Executive Officer of iPierian (acquired by BMS), ARRESTO (acquired by Gilead) and AVIDIA (acquired by AMGEN).

In addition to founding ARMO, he was the founder of ARRESTO, co-founder of TrueNorth (acquired by Bioverativ) and was a member of the start-up teams of InterMune (ITMN) and Dendreon (DNDN).

Dr. Van Vlasselaer currently serves on the boards of BLADE Therapeutics, Comet Therapeutics and RGENIX.

He has a degree in Zoology and a PhD in Immunology from the Catholic University of Leuven, Belgium.

He was a Post-Doctoral Fellow in the Division of Immunology and Rheumatology at Stanford University Medical School and DNAX Research Institute.

Dr. Van Vlasselaer has authored several peer reviewed scientific publications and book chapters and he is an inventor on multiple patents.


 LATEST MOVES FROM Switzerland 


POST Online Media Contact